John Dane Dodge II

Experience

• 

  Whitby Pharmaceuticals

  Jan 1987 - Feb 1990

  Sr. Oncology Pain Area Manager

  Launched Lortab (narcotic line for break through bone pain ). This provided me with my opportunity to gain experience in the medical oncology community.

• 

  Novartis

  Feb 1990 - Jan 1995

  Sr. Speciality Account Manager
• 

  Takeda

  Mar 1995 - Apr 2001

  Sr. Speciality Account Manager (Oncology, Urology, Gastroenterology)

  Multiple award winning career that allowed me to launch Lupron for prostate cancer and Prevacid for GERD. I earned several Presidents Club awards as well as other prestigious awards for my efforts.

• 

  Sanofi

  May 2001 - Feb 2004

  Sr. Speciality Account Manager (Urology, Cardiology, Psych)

  Launched new psychiatric division with focus on insomnia (Ambien). Spinoff opportunity within Sanofi to create special task force to focus on Urology / Cardiology was offered. Launched Plavix and Erexathon for BPH

• 

  OSI ( Eyetech) Biotech

  Feb 2004 - Jun 2007

  Sr. Retina Area Manager

  Multi award winning position where I Introduced the breakthrough drug, Macugen, for age-related wet macular degeneration, to retina specialists throughout Virginia.

• 

  GPC Biotech

  Jun 2007 - Nov 2007

  Oncology Account Manager

  Hired to launch Satraplatin for prostate cancer. Successfully completed training in Princeton only to have the drug voted down by ODAC. Company was dissolved.

• 

  Teva Pharmaceuticals

  Jan 2008 - Mar 2015

  Sr.Executive Hematology Oncology Account Specialist/ Regional Oncology Trainer

  Multiple award winning career at Teva Oncology (formally Cephalon Oncology) during which I launched Treanda (Bendamustine) for Chronic Lymphocytic Leukemia and Non Hodgkin's Lymphoma, Trisenox (Arsenic Trioxide) for Acute Promyelocytic Leukemia, Synribo (Omacetaxine) for Chronic Myeloid Leukemia, and Granix ( Filgrastim) a short acting GCSF as supportive care in the treatment of severe neutropenia. I was co-leader in competitive Intel task force in launch of Granix that lead to significant changes to business plan.My contributions and performance at Teva led to my being awarded the President’s Club Award several times for my territory comprising of the entire state of Virginia. I was the recipient of several distinguished awards including the 2008 Circle of Excellence Award, the 2009 and 2010 Presidents Club, and the 2012 and 2013 True North Award.I served on the Reimbursement Field Advisory Committee and Marketing Advisory Committee, and completed the Yellow Belt in Six Sigma and PCI Leadership Management Assessment. I maintained excellent relationships with my accounts, had access to hard or no-see accounts, and took pride in being the consummate teammate. Concurrently chaired the 2009 Leukemia and Lymphoma Society Light The Night Walk for the City of Richmond as well as acted as team captain for the Walk in the cities of Fredericksburg, Charlottesville, Virginia Beach, and Roanoke. Served as Chair of LLS Leukemia Cup Regatta for 7th year. Show less

• 

  Sandoz

  Mar 2015 - now

  My award winning position involves thorough knowledge of clinical, buy and bill, and managed markets of territory, including GPO’s, IDN’s, hospital health systems, 340B , Medicare Reimbursement, Pass Through status, as well as KOL development. Directly interact with private practices, cancer centers, hospitals health systems, office financial directors, doctors, nurses, reimbursement managers, clinical coodinators, nurse coordinators, and Hospitals- Director of Pharmacy, Pharmacy Business Director, and Clinical Oncology Director. Role is pivotal in decision making and pull-through for securing a WIN”. Position also allows for opportunity to enhance our position and support with patient advocacy. I am also lead on task force to develop KOL for biosimilar support. VA, WV, D.C, MD, and DE. Multiple awards for collaboration, cross functional leadership, teamwork, and going the extra mile for a teammate or customer. Show less Promoted to Managed Markets role that entailed direct responsibility with GPO, IDN, 340B, DSH contracting with customer base for all of Virginia, West Virginia, Washington D.C, Maryland, and Delaware. This encompasses all hospitals, academic health systems, cancer centers, and private practices. Personal interaction with key decision makers including CEO, CFO, Director of Pharmacy , Pharmacy Business Director, Reimbursement and Billing Manager, Clinical Director, Oncology Department, with the goal of conversion to our biosimilar Zarxio. Finally, to provide support in pull-through for converted accounts. Successful in winning accounts such as University of Virginia, Johns Hopkins, Medstar Heath Systems ( Georgetown University),Beebe Health System to name a few. Show less

  • Associate Director

    Mar 2015 - now

  • Oncology Biosimilar Institutional Portfolio Manager

    Mar 2015 - Jun 2024

  • Oncology Key Account Manager

    Dec 2015 - Jul 2016

  • Oncology Portfolio Account Specialist

    Mar 2015 - Dec 2015